About Senti Biosciences
Senti Biosciences is a company based in San Francisco (United States) founded in 2016 by Jim Collins, Wilson Wong, and Tim Lu.. Senti Biosciences has raised $158 million across 7 funding rounds from investors including Amgen, ARE and Mirae Asset. The company has 34 employees as of December 31, 2024. Senti Biosciences offers products and services including SENTI-202, SENTI-301A, and Gene Circuits Platform. Senti Biosciences operates in a competitive market with competitors including Caribou Biosciences, Poseida Therapeutics, Immunocore, Achilles Therapeutics and Tenaya Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 34 as on 31 Dec, 2024
- Founders Jim Collins, Wilson Wong, Tim Lu
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Senti Biosciences, Inc.
-
Annual Revenue
$0-100as on Dec 31, 2024
-
Net Profit
$-52.79 M43.19as on Dec 31, 2024
-
EBITDA
$-54.88 M10.8as on Dec 31, 2024
-
Total Equity Funding
$158 M (USD)
in 7 rounds
-
Latest Funding Round
$37.6 M (USD), Post-IPO
Dec 02, 2024
-
Investors
Amgen
& 26 more
-
Employee Count
34
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Senti Biosciences
Senti Biosciences is a publicly listed company on the NASDAQ with ticker symbol SNTI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Senti Biosciences
Senti Biosciences offers a comprehensive portfolio of products and services, including SENTI-202, SENTI-301A, and Gene Circuits Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets acute myeloid leukemia using off-the-shelf NK cells.
Treats hepatocellular carcinoma through engineered cell therapies.
Reprograms cells to sense and respond in cancer treatment applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Senti Biosciences
Senti Biosciences has successfully raised a total of $158M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $37.6 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $37.6M
-
First Round
First Round
(01 Jan 2018)
- Investors Count 27
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2024 | Amount | Post-IPO - Senti Biosciences | Valuation | Celadon Partners | |
| Dec, 2024 | Amount | Post-IPO - Senti Biosciences | Valuation | Celadon Partners | |
| Jun, 2024 | Amount | Grant - Senti Biosciences | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Senti Biosciences
Senti Biosciences has secured backing from 27 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, ARE and Mirae Asset. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Senti Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Senti Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Senti Biosciences Comparisons
Competitors of Senti Biosciences
Senti Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Caribou Biosciences, Poseida Therapeutics, Immunocore, Achilles Therapeutics and Tenaya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer
|
|
| domain | founded_year | HQ Location |
T-cell therapies targeting tumor neo-antigens for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Senti Biosciences
Frequently Asked Questions about Senti Biosciences
When was Senti Biosciences founded?
Senti Biosciences was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Where is Senti Biosciences located?
Senti Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Senti Biosciences?
Tim Lu is the current CEO of Senti Biosciences. They have also founded this company.
Is Senti Biosciences a funded company?
Senti Biosciences is a funded company, having raised a total of $158M across 7 funding rounds to date. The company's 1st funding round was a Grant of $8M, raised on Jan 01, 2018.
How many employees does Senti Biosciences have?
As of Dec 31, 2024, the latest employee count at Senti Biosciences is 34.
What does Senti Biosciences do?
Senti Biosciences was founded in 2016 and is headquartered in San Francisco, United States. A proprietary synthetic biology platform is utilized to engineer cell and gene therapies targeted at cancer. Therapeutic gene circuits are optimized for diverse applications in oncology. CAR-NK-based treatments are provided for various cancers and tumors, supporting advancements in the biotechnology sector.
Who are the top competitors of Senti Biosciences?
Senti Biosciences's top competitors include Immunocore, Achilles Therapeutics and Autolus.
What products or services does Senti Biosciences offer?
Senti Biosciences offers SENTI-202, SENTI-301A, and Gene Circuits Platform.
Is Senti Biosciences publicly traded?
Yes, Senti Biosciences is publicly traded on NASDAQ under the ticker symbol SNTI.
Who are Senti Biosciences's investors?
Senti Biosciences has 27 investors. Key investors include Amgen, ARE, Mirae Asset, HHS, and Allen & Company.
What is Senti Biosciences's ticker symbol?
The ticker symbol of Senti Biosciences is SNTI on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.